Introduction {#s1}
============

Herpes simplex viruses (HSV) are major global health problems. HSV serotype 1 (HSV-1) is associated primarily with oral mucocutaneous disease, sporadic encephalitis, and is a leading cause of corneal blindness worldwide, whereas HSV serotype 2 (HSV-2) is the leading cause of genital ulcerative disease and a major cofactor in fueling the HIV epidemic ([@bib28]; [@bib57]; [@bib25]). The World Health Organization estimated that over 500 million people are infected with HSV-2 worldwide with approximately 20 million new cases annually ([@bib40]). The extremely high prevalence of HSV-2 in sub-Saharan Africa (∼70%) ([@bib40]) may contribute more to the spread of HIV-1 than number of sex partners or other sexually transmitted infections ([@bib25]; [@bib12]). Moreover, as HSV establishes latency in neurons with frequent subclinical or clinical reactivations, there is a lifelong impact of infection. Notably, HSV-1 has emerged as a predominant cause of genital disease in the developed world ([@bib48]; [@bib58]; [@bib29]; [@bib6]). These epidemiological findings highlight the urgency to develop a safe and effective vaccine that protects against both serotypes.

Subunit vaccines comprised of the HSV-2 viral envelope glycoprotein D (gD-2) alone or combined with other envelope glycoproteins and with different adjuvants have predominated the HSV vaccine field for nearly 20 years ([@bib41]; [@bib18]; [@bib54]; [@bib5]; [@bib4]; [@bib37]). The rationale for gD-2 subunit vaccines included their safety and ability to elicit neutralizing antibody (Ab) responses in vitro. However, the clinical trial outcomes have been disappointing. For example, in the most recent efficacy trial, an HSV-2 gD adjuvanted subunit vaccine provided no protection against HSV-2 genital disease, but surprisingly provided 35% cross-protection against HSV-1 infection and 58% cross-protection against HSV-1 disease ([@bib4]). Neutralizing Abs (1:422 against HSV-1 and 1:97 against HSV-2) were detected in the serum, but were not measured in mucosal sites ([@bib2]; [@bib3]). The gD-2 subunit vaccine also elicited CD4^+^, but not CD8^+^ T cell responses; however, the cellular responses did not correlate with HSV-1 protection ([@bib3]). These findings suggest the need for more complex immunogens to elicit protective immune responses against both serotypes.

The efficacy of the live attenuated varicella zoster virus (VZV) (a related herpes virus) vaccine suggests that a similar approach for HSV may prove effective. However, preclinical studies with attenuated HSV vaccine candidates have yielded variable but incomplete protection against primary infection and latency ([@bib9]; [@bib53]; [@bib32]; [@bib51]). For example, *Shin* and *Iwasaki* found that a 'prime-pull' strategy, in which mice were first primed subcutaneously with an attenuated HSV deleted in thymidine kinase and then treated intravaginally with chemokines to recruit protective CD8^+^ T cells into the genital tract, was required for protection ([@bib51]). We adopted a different attenuated vaccine strategy based on an HSV-2 virus genetically deleted for the gene that encodes gD-2 (*U*~*S*~*6*) and complemented the virus to allow a first round of replication by growing it on Vero cells encoding HSV-1 *U*~*S*~*6* (gD-1, VD60 cells) ([@bib17]). The HSV-1 gD complemented HSV-2 mutant virus (designated HSV-2 Δ*gD*^−/+gD−1^) replicates in VD60 cells to high titers, but a single passage through non-complementing cells yields non-infectious progeny, reflecting the requirement for gD in entry and cell-to-cell spread. We evaluated this virus for safety, immunogenicity, and vaccine efficacy against intravaginal challenge and in a skin scarification model in different strains of mice. Subcutaneous prime and boost of mice with HSV-2 Δ*gD*^−/+gD−1^ protected against lethal challenge in both models and prevented the establishment of latency. Adoptive transfer experiments showed that protection was mediated by antibodies (Abs) and required both the Fcγ receptor and neonatal Fc receptor (FcRn).

Results {#s2}
=======

Immunization with HSV-2 Δ*gD*^*−/+gD−1*^ is safe and protects mice from intravaginal lethal challenge {#s2-1}
-----------------------------------------------------------------------------------------------------

We reasoned that deletion of gD-2, an envelope glycoprotein required for viral entry and cell-to-cell spread, would restrict infection to a single round of viral replication and thus provide a safe, highly attenuated candidate vaccine. Therefore, we constructed a variant of HSV-2(G) deleted for *U*~*S*~*6* (*gD*-2) ([@bib17]). The virus was subsequently subjected to three rounds of plaque purification and grew to high titers (10^8^ pfu/ml) when phenotypically complemented by growing the virus on VD60 cells, which express HSV-1 gD under the control of the *gD-*1 promoter. No plaques were observed when three independent plaque-purified isolates were grown to 10^8^ pfu on VD60 cells and then plated on non-complementing Vero cells. Moreover, no recombinants were detected by PCR, most likely reflecting differences in the regions flanking gD in VD60 cells and in HSV-2 ([Figure 1A](#fig1){ref-type="fig"}). Western blots show similar levels of expression of other HSV viral proteins when the deletion virus is grown on VD60 or Vero cells ([Figure 1B](#fig1){ref-type="fig"}).10.7554/eLife.06054.003Figure 1.Characterization of the Δ*gD*^*−/−*^ virus.(**A**) Alignment of the upstream and downstream regions of *gD* located within the HSV-1 BamHI J fragment encoded in VD60 cells and within the genome of Δ*gD*^−/−^ using LALIGN (ExPASy) ([@bib44]). Global alignments assess end-to-end sequences and local pairwise alignments search for regions with high identity. (**B**) Western blots of dextran gradient-purified virus isolated 24 hr after infection of VD60 (Δ**gD**^*−/+gD−1*^) and Vero (Δ*gD*^−/−^) cells. Protein expression was assessed for viral glycoproteins B (gB, *U*~*L*~*27*), gC (*U*~*L*~*44*), gD (*U*~*s*~*6*), gE (*U*~*s*~*8*), gH (*U*~*s*~*22*), gL (*U*~*L*~*1*), VP5 (*U*~*L*~*19*) and VP16 (*U*~*L*~*48*).**DOI:** [http://dx.doi.org/10.7554/eLife.06054.003](10.7554/eLife.06054.003)

To assess whether HSV-2 Δ*gD*^−/+gD−1^ is safe in vivo, severe combined immunodeficiency (SCID) mice were inoculated subcutaneously or intravaginally with the complemented HSV-2 Δ*gD*^−/+gD−1^ strain or parental HSV-2(G) virus ([Figure 2A](#fig2){ref-type="fig"}). SCID mice inoculated intravaginally with 10^7^ pfu of HSV-2 Δ*gD*^−/+gD−1^ manifested no signs of disease, whereas animals inoculated with 10^4^ pfu of HSV-2(G) quickly succumbed to the infection and manifested severe HSV-2-induced epithelial and neurological disease ([Figure 2B,C](#fig2){ref-type="fig"}). Subcutaneous inoculation with wild-type virus also induced disease (60% mortality with 10^5^ pfu), while no evidence of disease was observed following exposure to high doses of HSV-2 Δ*gD*^−/+gD−1^ in SCID mice. Moreover, no virus was detected in the neural tissue of SCID mice inoculated intravaginally with HSV-2 Δ*gD*^−/+gD−1^ by qPCR ([Figure 2D](#fig2){ref-type="fig"}).10.7554/eLife.06054.004Figure 2.HSV-2 Δ*gD*^*−/+gD−1*^ is attenuated in severe combined immunodeficiency (SCID) mice.(**A**) Survival of SCID mice inoculated with up to 10^7^ pfu of HSV-2 Δ*gD*^−/+gD−1^ or up to 10^5^ pfu of the parental HSV-2(G) strain either intravaginally (ivag) or subcutaneously (sc). Statistical significance was measured by log-rank Mantel--Cox test; \*\*p \< 0.01 for Δ*gD* and WT after ivag inoculation. (**B**) Epithelial and (**C**) Neurological disease scores for SCID mice inoculated with the different viruses at indicated doses. (**D**) HSV-2 DNA (qPCR, *U*~*L*~*30* gene) in genital tract and neural tissue samples at day 5 post-virus inoculation. The Ct cut off was determined with HSV-uninfected naïve samples. Statistical significance was measured by two-way ANOVA with Sidak\'s multiple comparisons test for (**B**, **C** and **D**); \*\*\*p \< 0.001. HSV-2 Δ*gD*^−/+gD−1^ and its parental strain are abbreviated as Δ*gD* and WT, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.004](10.7554/eLife.06054.004)

To determine whether vaccination with HSV-2 Δ*gD*^−/+gD−1^ induces protective immunity to wild-type HSV-2 intravaginal challenge, mice were primed and boosted subcutaneously (sc) with 5 × 10^6^ pfu (100 µl total volume) or with an uninfected VD60 cell lysate as a control. 3 weeks after the boost, the mice were challenged intravaginally with a clinical isolate of HSV-2 (strain 4674) ([@bib49]) equivalent to an LD~90~ (5 × 10^4^ pfu/mouse) and 10 times the LD~90~ (5 × 10^5^ pfu/mouse). Vaccinated mice were completely protected from lethal disease, whereas all of the control mice succumbed by day 8 post--challenge ([Figure 3A](#fig3){ref-type="fig"}). The majority of the vaccinated mice (14/20) showed no evidence of epithelial disease ([Figure 3B](#fig3){ref-type="fig"}) and none showed any signs of neurological disease ([Figure 3C](#fig3){ref-type="fig"}). The mice with epithelial signs recovered fully and HSV was detected by plaque assay in vaginal washes from vaccinated mice only on day 2 post--challenge but was cleared by day 4 post--challenge ([Figure 3D](#fig3){ref-type="fig"}). These findings suggest that the epithelial signs observed may reflect a local immune response and not ongoing viral replication. Moreover, no infectious virus was recovered from vaginal or neural tissue in HSV-2 Δ*gD*^−/+gD-1^-vaccinated mice at day 5 post-infection, but virus was readily detected from all of these sites in control-vaccinated mice ([Figure 3E](#fig3){ref-type="fig"}). Furthermore, we were unable to reactivate any virus from dorsal root ganglia (DRG) cultured ex vivo for 21 days ([Figure 3F,G](#fig3){ref-type="fig"}). In contrast, virus reactivated from DRG extracted from all control-vaccinated animals. In addition, HSV DNA (*U*~*S*~*6* gene) was not detected by qPCR in vaccinated mice (limit of detection 3 HSV-2 genome copies), but was detected in all controls ([Figure 3H](#fig3){ref-type="fig"}). Similar results were obtained using primers for a different viral gene, *UL30* (data not shown). These findings suggest that the vaccine prevents establishment of latency.10.7554/eLife.06054.005Figure 3.Vaccination with HSV-2 Δ*gD*^*−/+gD−1*^ protects mice against intravaginal lethal challenge.C57BL/6 mice were subcutaneously primed and boosted 3 weeks apart either with HSV-2 Δ*gD*^−/+gD−1^ or VD60 cell lysate (Control). 21 days after boost, mice were challenged with an LD~90~ of wild-type HSV-2(4674) or 10 × LD~90~. (**A**) Survival, (**B**) Epithelial and (**C**) Neurological disease scores were followed daily after challenge. (**D**) Viral titers in vaginal washes at days 2 and 4 after challenge (n = 10 mice pooled two per group, lines indicate means). (**E**) Viral titers in vaginal and neural tissue (including the dorsal root ganglia, DRG) at day 5 after challenge (n = 5, lines indicate means). (**F**) Ex vivo reactivation of neural tissue obtained from challenged mice (n = 5 per group). (**G**) HSV-2 pfu in the media of ex vivo reactivated neural tissue obtained from challenged mice (n = 5 mice per group, lines indicate means). (**H**) HSV-2 DNA (qPCR, *U*~*S*~*6* gene) of genital tissue and neural tissue at day 5 after challenge (n = 5, lines indicate means). (**I**) Survival of BALB/c mice that were primed, boosted and challenged as the C57BL/6 mice described above. (**J**) HSV-2 DNA (qPCR, *U*~*S*~*6* gene) in Control- and Δ*gD-*vaccinated BALB/c neural tissue at day 7 (n = 5, lines indicate means) and Δ*gD-*vaccinated BALB/c neural tissue at day 21 (n = 9, lines indicate means) after challenge. HSV-2 Δ*gD*^−/+gD−1^*-*vaccinated group vs Control-vaccinated group were compared by log-rank Mantel--Cox test (**A**, **I**), two-way ANOVA with Sidak\'s multiple comparisons test (**D***,* **E**, **G**, **H**) or unpaired *t*-test (**J**); \*\*\*p \< 0.001. HSV-2 Δ*gD*^−/+gD−1^ and Control are abbreviated as Δ*gD* and Ctrl, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.005](10.7554/eLife.06054.005)10.7554/eLife.06054.006Figure 3---figure supplement 1.Δ*gD*^*−/+gD−1*^-vaccinated cycling mice are protected against intravaginal HSV-2 challenge.C57BL/6 mice were treated (w/MPA) or not (w/o MPA) with medroxyprogesterone (MPA) 5 days previous to subcutaneous prime and boost 3 weeks apart either with HSV-2 Δ*gD*^−/+gD−1^ (Δ*gD*) or VD60 cell lysate (Control). 16 days after boost, all mice were treated with MPA and 5 days later challenged intravaginally with an LD~90~ of wild-type HSV-2(4674) (n = 5 mice per group). Statistical significance was measured by log-rank Mantel--Cox test; \*\*\*p \< 0.001, treatments vs Control.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.006](10.7554/eLife.06054.006)

Mice were pretreated with medroxyprogesterone (MPA) to hormonally synchronize them prior to immunization in the efficacy studies. However, MPA can modulate innate and adaptive immune responses ([@bib33]; [@bib56]). Therefore we conducted additional experiments with cycling and MPA treated mice. The vaccine protected 100% of mice independent of hormonal treatment ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In addition, mouse strains can differ in susceptibility and immune responses to pathogens. Therefore we also tested the efficacy of the vaccine against HSV-2 intravaginal infection in BALB/c mice. Consistent with the findings in C57BL/6 mice, 100% of HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice survived intravaginal challenge ([Figure 3I](#fig3){ref-type="fig"}) and no infectious virus or viral DNA was recovered from neural tissues at day 7 and 21 post-infection ([Figure 3J](#fig3){ref-type="fig"}).

HSV-2 Δ*gD*^*−/+gD−1*^ protects against disease in a skin scarification model {#s2-2}
-----------------------------------------------------------------------------

The majority of clinical HSV lesions are observed on the external genital skin rather than cervicovaginal sites. Therefore, we tested the vaccine for efficacy in a modified skin scarification model against both serotypes. The flank skin of C57BL/6 mice was depilated and scarified prior to direct inoculation of the skin with 5 × 10^4^ pfu (HSV-2(4674)) or 1 × 10^7^ pfu (HSV-1(17)) in 5 µl volume. The control-vaccinated (VD60 lysate) mice developed zosteriform lesions, neurologic disease and succumbed to infection following challenge with HSV-2, whereas HSV-1 produced more modest signs ([Figure 4A,B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). More importantly, the HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice showed minimal signs of epithelial disease (maximal disease score 1), no neurological signs and 100% survival after challenge with either serotype ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). No HSV was detected by titering or qPCR in day 14 skin biopsies or neural tissue from HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice; whereas virus was detected in 100% of control mice challenged with HSV-2 ([Figure 4D,E](#fig4){ref-type="fig"}).10.7554/eLife.06054.007Figure 4.Vaccination with HSV-2 Δ*gD*^*−/+gD−1*^ protects mice infected with HSV-2 and HSV-1 in a skin scarification model.Mice were subcutaneously primed and boosted 3 weeks apart either with HSV-2 Δ*gD*^−/+gD−1^, Control VD60 cell lysate or PBS. 3 weeks later, mice were depilated and challenged in the flank skin with PBS (mock), (**A**) 5 × 10^4^ pfu HSV-2(4674) or (**B**), 1 × 10^7^ pfu HSV-1(17). Representative images are shown. (**C**) Skin disease scores for HSV-2(4674)-challenged mice at days 3--11. (**D**) Viral titers from biopsies of skin or neural tissue obtained on day 6--7 (Control mice) and day 14 (HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice) (n = 5 mice per group, lines indicate means). (**E**) HSV-2 DNA (qPCR, *U*~*S*~*6* gene) in skin biopsies and neural tissue of Control mice (day 6--7) and HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice (day 14) challenged with virus (5 mice per group, lines indicate means). Statistical significance was measured by two-way ANOVA with Sidak\'s multiple comparisons test (**D** and **E**); \*\*\*p \< 0.001, Δ*gD*^−/+gD−1^*-*vaccinated group vs control group. HSV-2 Δ*gD*^−/+gD−1^ is abbreviated as Δ*gD*.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.007](10.7554/eLife.06054.007)10.7554/eLife.06054.008Figure 4---figure supplement 1.Vaccination with HSV-2 Δ*gD*^*−/+gD−1*^ protects mice infected with HSV-1 in a skin scarification model.Mice were subcutaneously primed and boosted 3 weeks apart either with HSV-2 Δ*gD*^−/+gD−1^ or Control VD60 cell lysate. 3 weeks later, mice were depilated and challenged in the flank skin with1 × 10^7^ pfu HSV-1(17). Skin disease scores shown for challenged mice at days 3--11. Viral titers from biopsies of skin obtained on day 7--8 (Control mice) and day 14 (HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice) (n = 5 mice per group, lines indicate means). Statistical significance was measured by unpaired *t*-test.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.008](10.7554/eLife.06054.008)

Passive transfer of sera from immunized mice protects naïve mice from intravaginal and skin challenge {#s2-3}
-----------------------------------------------------------------------------------------------------

To determine if protection could be transferred to naïve mice, 250 μl of serum (containing 750 μg of immunoglobulin administered intraperitoneally) or 3 × 10^6^ T cells (administered intravenously) isolated from the blood or spleen and lymph nodes of immunized mice, respectively, were administered to C57BL/6 mice. 48 hr later, the mice were challenged with 10^5^ pfu of HSV-2(4674) intravaginally. Mice treated with a single dose of immune serum displayed modest epithelial signs (mean score 2), but no neurologic disease with 100% survival ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). In contrast, mice that received T cells from immune mice or serum or T cells from the controls succumbed to disease. Depletion of immunoglobulins from the immune serum by passage on a Protein L column abolished the protective capacity. HSV-specific Abs were detected in vaginal washes in mice that received the immune, but not control serum ([Figure 5B](#fig5){ref-type="fig"}).10.7554/eLife.06054.009Figure 5.Serum from HSV-2 Δ*gD*^*−/+gD−1*^-vaccinated mice protects naïve mice against HSV-2 intravaginal and skin challenge.Mice were subcutaneously primed and boosted 3-weeks apart either with HSV-2 Δ*gD*^−/+gD−1^ or VD60 cell lysate (Control). 21 days later, blood and spleen were collected for serum and T cell purification and transferred intraperitoneally and intravenously, respectively, into naïve wild-type C57BL/6 mice. 24 hr and 48 hr after serum and T cell transfer, respectively, mice were challenged intravaginally with LD~90~ of HSV-2(4674) and followed for survival (n = 5 mice per group). Serum immunoglobulins were depleted using a Protein L column (**A**). (**B**) Transferred anti-HSV-2-antibodies were assessed by ELISA in vaginal washes of recipient mice (washes pooled from five mice in three independent experiments). (**C**) Pooled serum from Control- or HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice was transferred into naïve wild-type C57BL/6 mice. 24 hr after serum transfer, mice were depilated in the flank skin and challenged with HSV-2(4674) and followed for survival (n = 5 mice per group). (**D**) Viral titers in skin biopsies and neural tissue of mice receiving Control-serum (day 7) and Δ*gD*^−/+gD−1^-serum (day 14) (n = 5 mice per group). (**E**) HSV-2 DNA (qPCR, *U*~*S*~*6* gene) in skin biopsies and neural tissue of mice receiving Control-serum (day 7) and Δ*gD*^−/+gD−1^-serum (day 14) (n = 5 mice per group). Statistical significance was measured by log-rank Mantel--Cox test (**A** and **C**), *t*-test (**B**) and two-way ANOVA with Sidak's multiple comparisons test (**D**); \*\*p \< 0.01, \*\*\*p \< 0.001, treatment vs control. HSV-2 Δ*gD*^−/+gD−1^ is abbreviated as Δ*gD*.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.009](10.7554/eLife.06054.009)10.7554/eLife.06054.010Figure 5---figure supplement 1.Serum from HSV-2 Δ*gD*^*−/+gD−1*^-vaccinated mice protects naïve mice against epithelial and neurological disease after HSV-2 intravaginal and skin challenge.Serum from Control- (VD60 cell lysate), Δ*gD*^−/+gD−1^-vaccinated mice, or Δ*gD*^−/+gD−1^ serum depleted of immunoglobulins using a Protein L column was transferred intraperitoneally into naïve wild-type C57BL/6 mice. 24 hr later, mice were challenged intravaginally with LD~90~ of HSV-2(4674) and followed for (**A**) epithelial and (**B**) neurological disease (n = 5 mice per group). (**C**) Serum from Control- or HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice was transferred intraperitoneally into naïve wild-type C57BL/6 mice. 24 hr later, mice were depilated and challenged in the flank skin with HSV-2(4674) and followed for epithelial disease.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.010](10.7554/eLife.06054.010)

Intraperitoneal administration of serum also protected mice from skin disease. The immune sera treated mice survived challenge ([Figure 5C](#fig5){ref-type="fig"}) and developed moderate signs of epithelial disease (mean score of 2.2), which peaked on day 6 ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Moreover, no neurological signs were observed and no virus was detected in neural tissue by titering or qPCR ([Figure 5D,E](#fig5){ref-type="fig"}). In contrast, mice that received control serum developed severe epithelial and neurological disease and succumbed to the infection with 100% lethality.

HSV-2 Δ*gD*^*−/+gD−1*^ induces high levels of antibodies targeting multiple HSV proteins with antibody-dependent cell-mediated cytotoxicity (ADCC) activity {#s2-4}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

HSV-specific Ab responses were consistently observed with serum dilutions as high as 1:800,000 7 days post-boost ([Figure 6A](#fig6){ref-type="fig"}) and were detected in vaginal washes within 4 days of challenge, indicating transport of HSV Abs into the vaginal lumen ([Figure 6B](#fig6){ref-type="fig"}). The serum HSV-specific Abs exhibited low levels of neutralizing activity (1:5 dilution) ([Figure 6C](#fig6){ref-type="fig"}), but did display ADCC activity, which was reduced in the presence of anti-FcγR Ab ([Figure 6D](#fig6){ref-type="fig"}). The HSV-specific Abs in serum and vaginal washes were comprised predominantly of IgG2a and IgG2b ([Figure 6E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) and recognized multiple viral proteins on Western blots with HSV-2-infected cell lysates as the immunogen ([Figure 6F](#fig6){ref-type="fig"}). Serum from control-immunized and subsequently HSV-2 infected mice (obtained at day 8 post--challenge) recognized a more restricted set of proteins. Western blots with purified HSV-2 Δ*gD*^−/+gD−1^ or HSV-2 Δ*gD*^−/−^ indicate that the predominant antigen recognized by control-immunized, HSV-2-challenged, but not Δ*gD*^−/+gD−1^-vaccinated mice, is gD ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Blots with recombinant glycoprotein B-1 identify the ∼100 kDa band recognized by the Δ*gD*^−/+gD−1^-vaccinated immune serum as gB ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}).10.7554/eLife.06054.011Figure 6.Vaccination with HSV-2 Δ*gD*^*−/+gD−1*^ induces protective mucosal antibodies targeting multiple HSV proteins with ADCC activity.(**A**) Anti-HSV-2 antibodies detected by ELISA in serum samples at day 7 post-boost in mice subcutaneously primed and boosted 3-weeks apart with Δ*gD*^−/+gD−1^ or VD60 lysate (Control) (4 independent pools of serum from 5--10 mice each, results shown as means ± SD). (**B**) Anti-HSV-2 antibodies detected by ELISA in vaginal washes at day 7 post-boost and day 4 post--challenge with HSV-2(4674) (n = 5 mice per group, lines indicate means). (**C**) In vitro neutralizing activity of serum antibodies (1:5 dilution) obtained from HSV-2 Δ*gD*^−/+gD−1^- or Control-vaccinated mice against HSV-2 (left) and HSV-1 (right) (n = 5 mice per group, lines indicate means). (**D**) Antibody-dependent cell-mediated cytotoxicity (ADCC) using mouse splenocytes, HSV-2-infected Vero cells and serum obtained either from Control- (VD60 cell lysate) or HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice conducted in the absence or presence of anti-CD16/CD32 Ab to FcγRIII and FcγRII. % ADCC is defined as the percentage of dead (Live/Dead^+^) target cells within HSV-2 GFP^High^ positive cells. A representative dot blot is shown in the upper panel and lower panel shows results for five mice per group (lines indicate means). (**E**) Isotype of anti-HSV-2 serum antibodies obtained from five mice each that were either HSV-2 Δ*gD*^−/+gD−1^-vaccinated and HSV-2(4674)-challenged or Control-vaccinated and HSV-2(4674)-challenged (results shown as means ± SD). (**F**) Western blots of cellular lysates infected with HSV-2(4674) and probed with dilutions of sera obtained from VD60 lysate-vaccinated and then subsequently infected mice (Control-Challenged) or dilutions of sera from HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice 7 days post boost (Δ*gD*-Vaccinated); blots are representative of five independent experiments. HSV-2 Δ*gD*^−/+gD−1^-vaccinated groups were compared to control-vaccinated mice by two-way ANOVA with Sidak\'s multiple comparisons test (**A**, **B**, **D** and **E**) and unpaired *t-*test (**C**); \*p \< 0.05; \*\*p \< 0.01, \*\*\*p \< 0.001. HSV-2 Δ*gD*^−/+gD−1^ is abbreviated as Δ*gD*.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.011](10.7554/eLife.06054.011)10.7554/eLife.06054.012Figure 6---figure supplement 1.Characterization of vaginal wash and serum antibodies.(**A**) Isotypes of anti-HSV-2 antibodies in vaginal washes obtained at day 4 and day 8 post intravaginal challenge in mice that were immunized with HSV-2 Δ*gD*^−/+gD−1^ (Δ*gD*) or VD60 cell lysate (Control). Antibody responses are shown as means ± SD (n = 5 per group) and were compared by two-way ANOVA; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. (**B**) Western blots with sucrose gradient-purified Δ*gD*^−/+gD−1^ and Δ*gD*^−/−^ viruses (equivalent particle numbers based on a Western blot for VP5) probed with an anti-gD mAb (mAb (+)), sera from HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice day 7 post-boost (Δ*gD*) or sera from VD60 lysate-vaccinated mice day 7 post-intravaginal challenge with HSV-2(4674) (Ctrl + Challenge). (**C**) Western blots with purified recombinant glycoprotein B-1 (2 μg per lane) probed with an anti-gB mAb (mAb (+)), sera from VD60 lysate -vaccinated mice (Ctrl), HSV-2 Δ*gD*^−/+gD−1^-vaccinated mice day 7 post boost (Δ*gD*) or VD60 lysate-vaccinated mice day 7 post-intravaginal challenge with HSV-2(4674) (Ctrl + Challenge).**DOI:** [http://dx.doi.org/10.7554/eLife.06054.012](10.7554/eLife.06054.012)

Importantly, antibody-mediated protection was lost when serum was transferred to FcγR and FcRn knock-out mice ([Figure 7A,B](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}). HSV-specific Abs were detected in vaginal washes of the FcγR^−/−^ mice, but failed to provide protection, whereas Abs were not detected in vaginal washes from FcRn^−/−^ mice consistent with the role of FcRn in transport of Abs from serum to the mucosa ([@bib38]) ([Figure 7C,D](#fig7){ref-type="fig"}).10.7554/eLife.06054.013Figure 7.Antibody-mediated protection requires FcγR and FcRn expression.Survival of (**A**) FcγR^−/−^ and (**B**) FcRn^−/−^ mice that were either transferred serum obtained from Control- (VD60 cell lysate) or HSV-2 Δ*gD*^−/+gD−1^-vaccinated wild-type mice and then challenged intravaginally with HSV-2(4674) (n = 5 mice per group). Detection of HSV-specific Abs by ELISA in pooled vaginal washes (n = 3 pools) of (**C**) FcγR^−/−^ and (**D**) FcRn^−/−^ mice receiving serum (intraperitoneally) from control- (VD60 cell lysate) or HSV-2 Δ*gD*^−/+gD−1^-vaccinated wild-type mice. Survival curves were compared using log-rank Mantel--Cox test (**A** and **B**) and antibody titers using unpaired *t*-test (**C** and **D**); \*\*\*p \< 0.001. HSV-2 Δ*gD*^−/+gD−1^ is abbreviated as Δ*gD*.**DOI:** [http://dx.doi.org/10.7554/eLife.06054.013](10.7554/eLife.06054.013)10.7554/eLife.06054.014Figure 7---figure supplement 1.Antibody-mediated protection requires FcγR and FcRn expression.Epithelial and neurological disease scores in (**A**, **B**) FcγR^−/−^ and (**C**, **D**) FcRn^−/−^ mice receiving serum from control- or HSV-2 Δ*gD*^−/+gD−1^-vaccinated wild-type mice and then challenged intravaginally with HSV-2(4674) (n = 5 mice per group).**DOI:** [http://dx.doi.org/10.7554/eLife.06054.014](10.7554/eLife.06054.014)

Discussion {#s3}
==========

The HSV vaccine field has focused most of its efforts on the induction of neutralizing Abs to gD as the major determinant of protection. The current study challenges this paradigm. We found that a live attenuated virus deleted in HSV-2 gD protects mice from vaginal, skin, and neuronal disease. Specifically, we observed no evidence of neurological disease in any model and could not detect virus in DRG of vaccinated mice by ex vivo plaque assays or by qPCR with a lower limit of detection of three viral genomes. The vaccine was effective in C57BL/6 and BALB/c mice and elicited high titers of HSV Abs (1:800,000) that were capable of passively protecting mice from both intravaginal and skin challenges. Notably, the Abs had low levels of neutralizing activity but did elicit ADCC and were able to passively transfer protection with a single dose of immune serum. The HSV-specific Abs could not be detected in vaginal washes of vaccinated mice, but were rapidly recruited into the vaginal lumen following intravaginal challenge and were associated with rapid clearance of the virus. Notably, the vaginal wash Abs were predominantly IgG, not IgA (data not shown), which is consistent with prior studies that have shown that while the predominant immunoglobulin by weight in the vaginal mucus of immune mice is secretory IgA, HSV-specific Abs are almost entirely IgG ([@bib47]; [@bib46]). The HSV-specific Abs were likely critical for protection as evidenced by the studies with FcRn knockout mice. Passive protection was also lost in FcγR knockout mice highlighting the role of Fc-mediated effector mechanisms.

These findings differ from those obtained with other subunit or attenuated vaccine candidates. The first attenuated vaccine to be evaluated clinically was a virus deleted in glycoprotein H (gH, *U*~*L*~*22*). Unlike the data presented here with the HSV-2 Δ*gD* virus*,* the gH deletion viral vaccine did not prevent the establishment of latency in mice ([@bib52]), was not shown to passively transfer protection and failed to reduce recurrences when evaluated as a therapeutic vaccine in a clinical trial ([@bib20]). More recently, a virus deleted in HSV-2 *U*~*L*~*5* and *U*~*L*~*29*, which is defective in HSV DNA replication, has been advanced to a Phase 1 study. This deletion virus also differs from the HSV-2 Δ*gD*^−/+gD−1^ vaccine candidate described here in that it does not induce as high an Ab response, has not been shown to passively protect, and did not prevent the establishment of latency as low levels of viral DNA were detected in the DRG following both immunization and viral challenge ([@bib30], [@bib32], [@bib31]; [@bib22]). Notably, the *U*~*L*~*5*/*U*~*L*~*29* deletion virus expresses gD at levels similar to that of wild-type virus, but lower levels of gB ([@bib19]). Thymidine kinase (tk) deletion viruses, which have been used to study HSV immunogenicity because they are attenuated in mice (but not humans), express the full repertoire of viral proteins including gD. Protection following immunization with tk-deletion viruses requires anti-HSV-2 T cells in the genital tract ([@bib42]; [@bib51]) and serum from mice immunized with this tk-deletion virus has not been shown to passively transfer protection ([@bib43]; [@bib42]).

Possibly, deletion of gD, which is immunodominant as evidenced by the immune response in control, HSV-2 challenged mice ([Figure 6F](#fig6){ref-type="fig"}) and by clinical data showing that the majority of HSV-infected individuals have neutralizing Abs to gD ([@bib11]), unmasks viral antigens important in generating a protective humoral response. Additionally, gD may modulate immune responses through its interactions with herpesvirus entry mediator (HVEM) on immune cells ([@bib36]; [@bib1]; [@bib55]; [@bib35]; [@bib27]; [@bib50]). Interactions between gD and HVEM may skew the immune response towards neutralizing Abs whereas in the absence of the gD-HVEM interaction or yet undiscovered immunosuppressive functions of gD, the host may mount a polyantigenic IgG2 dominant response capable of eliciting FcR-mediated protection. This hypothesis will be tested in future studies by: (1) comparing, for example, the immune response to virus in mice deficient for HVEM, (2) examining the immune response to the HSV-2 Δ*gD*^−/+gD−1^ vaccine when combined with the gD subunit vaccine, or (3) isolating mutant forms of gD that have lost immunosuppressive functions.

The inability of gD to elicit protective immunity against HSV-2 is highlighted by the results of the clinical trials with an adjuvanted gD subunit vaccine ([@bib41]; [@bib18]; [@bib34]; [@bib5]; [@bib4]). An additional mechanism that may contribute to the protection observed with the HSV-2 Δ*gD*^−/+gD−1^ vaccine and to the observation that it induces Abs to multiple viral proteins is that by deleting the gene for gD, which is required for cell-to-cell spread, the cells initially infected by the complemented virus may function as a 'factory' generating viral proteins and 'defective' particles that are immunogenic. Consistent with this is the observation that heat-killed HSV-2 Δ*gD*^−/+*gD−1*^ failed to protect mice from vaginal challenge (data not shown).

In addition to its unique ability to generate high levels of Abs capable of translocating to mucosal sites and to prevent virus from reaching neuronal tissue following intravaginal or skin challenge, the HSV-2 Δ*gD*^−/+gD−1^ virus is also an attractive vaccine because of its safety. The virus induced no disease in SCID mice inoculated with 1000 times the lethal dose of wild-type virus and to date we have observed no recombinants either by plaque assay or PCR. This likely reflects that the virus is propagated on an HSV-1 and not an HSV-2 complementing cell line. The flanking regions of gD in HSV-1 and HSV-2 share approximately 54% and 73% identity within the 5′ and 3′ region of the *U*~*S*~*6* gene, respectively (HSV-1(KOS) vs HSV-2(HG52), NCBI genome, [Figure 1A](#fig1){ref-type="fig"}). This level of homology makes recombination highly unlikely.

It remains to be determined whether pre-existing immunity to HSV-1 will impact the immunogenicity of the HSV-2 Δ*gD*^−/+gD−1^ vaccine as was shown with the gD subunit vaccine ([@bib54]) This may be less of a problem with HSV-2 Δ*gD*^−/+gD−1^ as it elicits a polyantigenic response whereas infection primarily elicits Abs to gD as evidenced by the immunoblots. If future studies suggest this is a problem, an alternative strategy is to complement the HSV-2 Δ*gD^−/+gD−1^*virus with gD from a nonhuman herpes virus or a chimeric gD ([@bib59]). Ideally the development of new mouse models of HSV latency and reactivation will allow us to explore the efficacy of HSV-2 Δ*gD*^−/+*gD−1*^ as a therapeutic vaccine.

The demonstration that this vaccine strain confers protective Abs against skin and intravaginal challenge that function through the Fc receptor highlights the importance of ADCC and antibody-mediated phagocytosis. Consistent with this concept are the results of the HIV RV144 vaccine trial, which found that non-neutralizing antibodies that mediate ADCC and antibody-mediated phagocytosis contributed to protection against HIV ([@bib8]). Similar findings have been observed in nonhuman primate studies of SHIV ([@bib24]; [@bib7]). Moreover, recent studies suggest that Ab--FcγR interactions are required to mediate protection against influenza ([@bib21]). Together these findings suggest that the HSV-2 Δ*gD^−/+gD−1^*vaccine provides a model to elicit such protective responses and indicate that it may be an ideal vaccine vector for other pathogens that enter through these sites.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

Experiments were carried out with approval from the Albert Einstein College of Medicine Institutional Animal Care and Use Committee, Protocol \#20130913. Female C57BL/6 (wild-type), BALB/c (wild-type), severe combined immunodeficiency (SCID, BALB/c background), and FcRn^−/−^ (B6.129X1-*Fcgrt*^*tm1Dcr*^/DcrJ) mice were purchased from the National Cancer Institute (NCI, Frederick, MD) or Jackson Laboratory (JAX, Bar Harbor, ME) at 4--6 weeks of age. Female FcγR^−/−^ (B6.129P2-*Fcer1g*^*tm1Rav*^ N12) mice were purchased from Taconic (Albany, NY) at 4--6 weeks of age.

Cell lines and viruses {#s4-2}
----------------------

CaSki (human cervical epithelial cell line; CRL-1550; American Type Culture Collection \[ATTC\], Manassas, VA, USA), Vero (green monkey kidney cell line; CCL-81; ATCC) cells, human keratinocytes (HaCAT, provided by David Johnson, Oregon Health & Sciences University, Portland, OR), and VD60 cells (Vero cells encoding *gD-1* under the endogenous gene promoter \[[@bib39]\]) were passaged in DMEM supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento, CA). Splenocytes were obtained by generating a single cell suspension from harvested spleens from animals and subsequently, red blood cells were lysed with ACK lysis buffer (Gibco, Grand Island, NY). Splenocytes were then resuspended in complete RPMI media until use. Construction of the HSV-2 Δ*gD*^−/+gD−1^ virus in the HSV-2(G) ([@bib23]) genetic background has been previously described by our group ([@bib17]). Briefly, 1,000 bp upstream and downstream regions of the *U*~*S*~*6* gene were PCR-amplified using viral genomic DNA (HSV-2(G)) with primers LL-V91I-US6 TTTTTT TTCCAT AAATTG GAAAGG GAACAG CGACCA AATGTC AC and LR-V91I-US6 TTTTTT TTCCAT TTCTTG GTGATA CGCGAT GCACAC GAAAAA CG for the upstream region of *U*~*S*~*6* and primers RL-V91I-US6 TTTTTT TTCCAT AGATTG GTTCCC CGCTCC CGTGTA CC and RR-V91I-US6 TTTTTT TTCCAT CTTTTG GCGGGG GCGCCT GTATCG G for the downstream region of this gene. Stocks of HSV-2 Δ*gD*^−/+gD−1^ virus were propagated on complementing VD60 cells and titered on VD60 and Vero cells. HSV-2(4674) ([@bib45]) was propagated on HaCAT cells. HSV-1(17) ([@bib10]), HSV-2(G) ([@bib23]), HSV-1(F) ([@bib23]) and HSV-2(333)ZAG ([@bib45]), a recombinant virus expressing the green fluorescent protein (GFP) were propagated on Vero cells. Concentrated viral stocks were stored at −80°C and diluted in PBS to the desired concentration when needed.

Immunization, antibody passive transfer, and T cell adoptive transfer {#s4-3}
---------------------------------------------------------------------

5 days prior to immunization, mice were treated subcutaneously with 2.5 mg of medoxyprogesterone acetate (MPA; Sicor Pharmaceuticals, Irvine, CA). All prime immunizations were given subcutaneously (sc, medial to the hind limb and pelvis) with 5 × 10^6^ pfu of HSV-2 Δ*gD*^−/+gD−1^ or an equal amount of VD60 cell lysate (Control). 3 weeks after initial immunizations, a boosting dose of 5 × 10^6^ pfu of Δ*gD*^−/+gD−1^ or VD60 cell lysate was administered. For adoptive transfer of T cells, spleens were harvested from immunized mice 3 weeks after the boosting dose. Splenocytes obtained by single cell suspensions from harvested spleens were then treated with ACK Lysing buffer (Gibco) to remove erythrocytes and resuspended in MACs buffer (2% heat-inactivated FBS, 2 mM EDTA in PBS). T cells were magnetically purified via negative selection (Pan T Cell Isolation Kit II, Miltenyi Biotec, Germany) using LS columns. Before inoculation into recipient mice, purity and viability of cells were verified by flow cytometry and trypan blue staining. A total of 3 × 10^6^ T cells were transferred into recipient mice intravenously through the tail. Alternatively, serum was collected from blood and a volume of 250 µl containing 750 µg of total IgG (detected via anti-mouse IgG ELISA) was transferred into recipient mice intraperitoneally 24 hr before intravaginal challenge of HSV-2. In select experiments, serum Ig was depleted by passing the serum through columns containing Protein L (GE healthcare Life Sciences, Piscataway Township, NJ).

HSV-2 and HSV-1 infections {#s4-4}
--------------------------

Mice were treated with MPA and challenged 5 days later with HSV-2(4674) 3 weeks after the vaccine boosting dose with 5 × 10^4^ plaque forming units (pfu, LD~90~) or 5 × 10^5^ pfu (10× LD~90~) of HSV-2(4674) intravaginally and monitored and scored for disease for 14 days as previously described ([@bib45]). For safety studies, unimmunized SCID mice were treated with MPA and inoculated 5 days later intravaginally or subcutaneously with HSV-2 (4674) or Δ*gD*^−/+gD−1^ either with 30 µl or 100 µl total volume, respectively. 150 µl of sterile PBS containing protease inhibitor (F Hoffmann-La Roche AG, Switzerland) was used to perform intravaginal washes for antibody and viral load quantification. Epithelial disease for intravaginal infections was scored as follows: (1) mild erythema, (2) hair loss, erythema, edema, (3) severe edema, hair loss, lesion formation, (4) severe ulcerations, multiple lesions and (5) death. Neurological disease for intravaginal infection was scored as follows: (1) urinary retention, (2) urinary retention and constipation, hind-limp paresis, (3) hind-limb paralysis (one leg), (4) complete hind limb paralysis (both legs), and (5) death. Mice were euthanized at a score of 3 or 4 and assigned a score of 5 on subsequent days for statistical analyses. For HSV skin infections, a protocol modified from [@bib26] was used. Briefly, mice were depilated on the right flank with Nair and allowed to rest for 24 hr. Depilated mice were anesthetized with isoflurane (Isothesia, Henry-Schein), then abraded on the exposed skin with a disposable emory board for 20--25 strokes and subsequently challenged with 5 × 10^4^ pfu of HSV-2(4674) or 1 × 10^7^ pfu of HSV-1(17) in 5 µl deposited on the abraded skin. Mice were then anesthetized for an additional 5 min to allow the virus inoculum to dry. Mice were monitored for 14 days and scored for signs of disease. Epithelial disease in the skin scarification model was scored as follows: (1) primary lesion or erythema, (2) distant site zosteriform lesions, mild edema/erythema, (3) severe ulceration and edema, increased epidermal spread, (4) hind-limb paralysis and (5) death. Mice that were euthanized at a score of 4 were given a value of 5 the next day.

Virus detection in vaginal washes and tissue and ex-vivo reactivation in neural tissue {#s4-5}
--------------------------------------------------------------------------------------

For pfu detection in tissue samples of mice inoculated and/or challenged with HSV, genital tract, skin, or dorsal root ganglia (including sciatic nerve from hind limb to spinal cord) were weighed and homogenized in serum-free Dubecco\'s Modified Eagles Medium (DMEM, Gibco) using RNase-free pestles. Homogenized tissues were then sonicated for 30 s at maximum strength and centrifuged at 10,000×*g* for 5 min. Supernatants were then overlaid on confluent Vero cell monolayers (2 × 10^5^ cells/well in a 48-well plate) for 1 hr. Wells were washed with PBS, then 199 medium (Gibco) containing 1% heat-inactivated FBS and overlaid with 0.5% methylcellulose and incubated at 37°C for 48 hr. Cells were fixed with 2% paraformaldehyde, stained with a crystal violet solution and the number of plaque forming units (pfu) were quantified. Vaginal washes from mice obtained after virus inoculation were plated neat or diluted in PBS on confluent Vero cell monolayers (2 × 10^5^ cells/well in a 48-well plate) and viral pfu were quantified as described above. Data are presented as log~10~ pfu per gram of tissue. For ex-vivo HSV reactivation, neural tissue obtained at day 5 post--challenge was excised, cut into 3--4 pieces and cultured with confluent Vero cell monolayers in serum-free DMEM in 60 × 15 mm tissue culture dishes (Corning). Dishes were observed daily up to 21 days post co-culture for cytopathic effect with media exchanged every 2 days. Supernatants were harvested every other day to measure viral pfu by standard plaque assay.

HSV-2 RT-qPCR analysis {#s4-6}
----------------------

DNA was extracted from weighed tissue samples using DNeasy Blood and Tissue (Qiagen) following the manufacturer\'s recommendations. Extracted DNA was then normalized to 10 ng of DNA per reaction and viral DNA quantified using real-time quantitative PCR (RT-qPCR, qPCR) using ABsolute qPCR ROX Mix (Thermo Scientific). Primers for HSV-2 *gD* (*U*~*S*~*6*) and polymerase (*U*~*L*~*30*) were purchased from Integrated DNA Technologies (*U*~*S*~*6* cat: 117920498 and *U*~*L*~*30* cat: 1179200494) and used to detect viral genome DNA. To determine the number of HSV-2 genome copies, HSV-2 viral DNA was used as a standard curve ([@bib13]). Samples that read three or less copy numbers were considered negative. Data are presented as log~10~ HSV-2 copy numbers per gram of tissue.

Antibody detection by ELISA {#s4-7}
---------------------------

Serum was obtained from individual mice at 1 week post-prime, at boost, 3 weeks post-boost, and 8 days after intravaginal challenge with HSV-2. Vaginal washes were collected in 150 µl PBS containing protease inhibitor at different time points after sc boost with Δ*gD*^−/+gD−1^ or intravaginal challenge with HSV-2. For HSV-2 specific antibody detection, Vero cells were mock-infected or infected with HSV-2(4674) and 24 hr later sonicated for 30 s and then coated on 96 well MaxiSorp ELISA plates (Nunc, NY) at a concentration of 45 µg cell lysate/well at 4°C overnight. Cell lysates were then further permeabilized with PBS/0.1% Triton X-100 buffer and fixed with 1% formaldehyde. Serum and vaginal washes obtained from individual mice were serially diluted and overlaid in duplicates onto cell lysate-coated wells and incubated at RT for 2 hr. Wells were washed with PBS/0.05% Tween 20 buffer five times and incubated with purified biotin anti-mouse Ig κ or biotin anti-mouse IgG1, IgG2a, IgG2b, or IgG3 at 1 µg/ml (Becton Dickenson, San Diego) for an additional 2 hr at RT. Next, cell lysates were washed as above and incubated with HRP-conjugated streptavidin (Becton Dickenson, San Diego) for 30 min at RT and then developed with TMB substrate (BD OptEIA) for 5 min. The reaction was stopped with 2 N H~2~SO~4~. Wells were read on a SpectraMax (M5 series) ELISA plate reader at an absorbance of 450 nm. The resulting absorbance was determined by subtracting values obtained for uninfected cell lysates to values obtained with infected cell lysates at a serum dilution of 1:2500 or 1:100 (total Ig or isotype specific, respectively) and at a 1:5 dilution for vaginal washes.

Neutralization assay {#s4-8}
--------------------

Serial dilutions of control and immune serum from 1 week post-boost were inactivated (56°C for 30 min) and then incubated at a 1:1 ratio with 50 pfu of HSV-2(4674) or HSV-1(F) in a 96-well plate at 37°C for 1 hr. Virus-antibody complexes were then overlaid onto confluent Vero cells in a 48-well plate for 1 hr at 37°C. Wells were then washed with PBS and subsequently with 500 µl 199 medium (Gibco) containing 1% heat-inactivated FBS with 0.5% methyl cellulose and incubated for 37°C for 48 hr. Plaques were quantified and percent neutralization was determined as the reduction of HSV-2 plaques compared to control (50 pfu HSV-2 in media).

Antibody dependent cellular cytotoxicity assay {#s4-9}
----------------------------------------------

Vero cells (used as target cells) were infected with HSV-2:GFP(333)ZAG at an MOI of 1 pfu/cell. 18 hr post-infection cells were harvested via CellStripper (Corning) and labeled with CellTrace Violet (Invitrogen, Grand Island, NY) at 1.25 µM. Labeled infected cells were then incubated with heat-inactivated serum from control or vaccinated individual mice at a 1:2 dilution for 15 min. Splenocytes from naïve mice were treated with ACK Lysing Buffer (Gibco) to remove erythrocytes and used as effector cells. Where indicated, effector cells were either treated or not with FCR-4G8 (anti-FcγRIII/II, anti-mouse CD16/32, Invitrogen, Grand Island, NY) at 2 µg/10^6^ cells. Co-cultures were performed at an effector cell to target cell ratio of 25:1 for 4 hr. Effector/target and target cells were then stained with Live/Dead Red fixable dye (Invitrogen) for 15 min and subsequently washed and resuspended in FACs buffer (2% heat-inactivated FBS, 2 mM EDTA in PBS). The percentage of dead HSV-2-infected target cells was determined on a 5-laser LSRII flow cytometer (Becton Dickenson, San Diego, CA) at the Einstein Flow Cytometry Core Facility. Final analysis was carried out using FlowJo software version 10 (Tree Star, Inc., Ashland, OR).

Western blots {#s4-10}
-------------

Stocks of HSV-2 Δ*gD*^*−/+gD−*1^ and Δ*gD*^*−/−*^ were propagated on VD60 or Vero cells and purified using dextran or sucrose gradients as previously described ([@bib17]) and then analyzed for viral protein expression by performing Western blots. Equivalent numbers of viral particles (based on Western blot probing with antibody to the viral capsid protein, VP5 \[[@bib15]\]) were loaded on gels, proteins separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with anti-HSV-2; gC (H1196), anti-gE (101), anti-VP16 (VA16), anti-VP5 (3B6), anti-gB (10B7), anti-gD (0191) from Santa Cruz Biotechnology (Santa Cruz, CA) and anti-gH-gL (CH31, gift from R Eisenberg and G Cohen, University of Pennsylvania) as previously reported ([@bib16]). Serum immune-target profiling was done by performing Western blots with 10 µg of HSV-2(4674) infected Vero cell lysates per lane or equivalent particle numbers (based on Western blots for VP5) of HSV-2 Δ*gD*^*−/+gD−*1^ and Δ*gD*^*−/−*^ purified virus, and probing with serial dilutions of immune or control serum obtained 1 week post-boost or 8 days post-intravaginal challenge, respectively. Alternatively, Western blots were performed using 2 µg of recombinant glycoprotein B-1 produced in baculovirus and purified on a CL-68 sepharose column (17-0467-01, GE Healthcare, Sweden) as previously reported ([@bib14]). The anti-gB-1/gB-2 monoclonal antibody 10B7 and the anti-gD-1 monoclonal antibody 0191 (Santa Cruz Biotechnology) were used as positive controls. Blots were incubated with immune and control serum for 16 hr at 4°C. After repetitive washes, bound antibodies were detected using goat anti-mouse-HRP secondary antibody (Bio Rad, Hercules, CA).

Statistical analysis {#s4-11}
--------------------

Results were compared by two-way analysis of variance (two-way ANOVA) with multiple comparisons or unpaired *t* tests using GraphPad Prism version 6 (San Diego, CA). Mantel--Cox survival curves were compared by log rank tests. p values \<0.05 (\*), \<0.01 (\*\*), \<0.001 (\*\*\*) were considered significant.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease" for consideration at *eLife*. Your article has been favorably evaluated by Randy Schekman (Senior editor) and 3 reviewers, one of whom served as a guest Reviewing Editor.

Two of the three reviewers, Susan Pierce and Andrew McMichael, have agreed to reveal their identity.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The three reviewers were very positive regarding this manuscript. The six (major) points raised by reviewer \#1 should be addressed by the authors. This need not involve additional experimentation. Finally, please discuss the points brought up by reviewers \#2 and \#3. No new experiments are required.

Reviewer \#1

In their manuscript, Petro and colleagues describe a novel HSV-2 vaccine concept based on a gD deletion mutant. The authors show that the vaccine strain is only able to undergo a single cycle of replication in non-complementing cells and is safe in SCID mice at high doses. Furthermore, the construct protects from HSV-2 induced neurological and epithelial disease in mice and cross-protection in a skin scarification mouse model against HSV-1 is demonstrated as well. Interestingly, the authors identify ADCC as mechanism of protection. The study is important, innovative and certainly well done. However, there are some issues that require the authors' attention.

Major points:

1\) A live attenuated VZV vaccine (Varivax/Zostervax) is currently used in the US. Although this vaccine is highly efficacious the immune response is short-lived and re-immunization is required. The authors show protection after a relatively short time interval (3 weeks post boost). Do the authors foresee the same problem with their HSV-2 vaccine? How long lasting is the immune response?

2\) The vaccine construct carries a HSV-1 gD protein. Approximately 54% of the US population has pre-existing immunity against HSV-1 (Bradley et al., JID, 2013). This could strongly impact on vaccine efficacy in humans. Would a complementing gD from a non-human herpesvirus be a better choice? The authors should discuss this.

3\) The authors show crossprotection/crossneutralization against HSV-1. Is this crossprotection ([Figure 4B](#fig4){ref-type="fig"} and [Figure 6C](#fig6){ref-type="fig"}) induced by the HSV-1 gD on the virus surface or not? No quantitative data is provided in [Figure 4](#fig4){ref-type="fig"} for the HSV-1 challenge. The authors should add disease scores and virus titers.

4\) The authors measure IgG in vaginal washes and use a neonatal FcR KO model to show that mucosal antibody is important. However, mucosal IgA is not discussed. Was that measured? Which role does it play?

5\) In [Figure 5](#fig5){ref-type="fig"}, the authors show that passive transfer of sera from vaccinated mice protects naive mice from challenge. The authors include a group of mice that receive \'Ig\' depleted serum. Animals in this group survive three days longer than mice in the other control groups and this result is likely statistically significant. Is this a technical issue with Ig depletion?

6\) The authors show that the deletion of the immunodominant gD from their virus re-directs the immune response towards the less immunogenic gB, a concept that has also been proposed for HA stalk-based influenza virus vaccines. Despite high titers of antibodies against gB, the neutralization titers are very low, which is in contrast to findings with gB subunit vaccines which usually induce robust neutralization titers. The authors should discuss this.

Reviewer \#2:

In this manuscript, the authors explore the efficacy of using a novel mechanism to attenuate Herpes simplex virus (HSV) 2 for use as a vaccine. HSV infections are an enormous global health problem and at present there is no HSV vaccine. Consequently new approaches to vaccine design are badly needed. The authors attenuate HSV-2 by deleting glycoprotein D (gD-2) and complementing the loss by a single round of replication of the virus on cells expressing HSV-1 gD (ΔgD^-/+gD-1^). The ΔgD^-/+gD-1^ virus when used as a vaccine should only replicate once in the host. To my mind the results presented here are remarkable. Subcutaneous immunization with ΔgD^-/+gD-1^ completely protected against intravaginal or skin challenge and prevented the establishment of latency. These data are convincing. Concerning the immune mechanisms underlying protection the authors provide evidence that protection can be transferred by Ig from immunized mice and requires that the recipient mouse express FcgammaR (presumably to mediate antibody-dependent cellular cytotoxicity as the Ig is poorly neutralizing but has ADCC activity) and FcRn (presumably to mediate transfer of Ig into the vaginal lumen).

The puzzling result in terms of immune mechanism is the dramatic effect of the presence of gD-1 on the Ab response. When gD is expressed the Ab response is almost entirely gD-specific and the Abs are neutralizing. In the absence of gD antibodies specific for many HSV proteins are made. This may simply be due to an extreme immunodominance of gD. It would seem that achieving such dominance would require that gD-specific B cells have a strong advantage over B cells recognizing other HSV antigens in germinal center reactions. Perhaps immune cells, for example, T follicular helper cells that have receptors for gD, synergize with gD-specific B cells. One way to approach the question would be to determine if gD expressing HSV induces only gD-specific response in mice deficient for the known gD receptors, i.e. CD155, CD112. Such experiments, while of interest, are certainly not required to support the conclusions drawn here.

Reviewer \#3:

This manuscript describes a novel approach to HSV2 vaccination in mice. They find that deletion of the immunodominat gD protein in the virus elicits non-neutralizing antibodies which protect against challenge very impressively. They use a variety of readouts, all giving the same answer.

They show that the protection is mediated by antibody, because passive transfer protects though not if Ig depleted. They show that the protection is Fc dependent and go on to show that it is likely to act through ADCC. Whether this is the direct mechanism responsible is less clear but there is at least a good correlation between this assay in vitro and protection.

There are important general messages here. Neutralizing antibody is not essential for protection. That is known, though often ignored, in other virus infections; here it is very well illustrated and shown that such antibodies can be harnessed by vaccination to give protection. Secondly the immunodominant antigen may not elicit protective antibody but subdominant immunogens might; genetically manipulated vaccines offer a way to address that, though what determines immunodominance often remains a mystery.

Can the findings be generalized to other infections? They make a reference to the RV144 HV vaccine trial where some protection was given by non-neutralizing antibodies. It would be good to cite other more convincing examples, if they exist.

A small point that is relevant to human vaccinology. BALB/c and C57B6 mice are often used to test immunogens and for challenges. However in human terms these are just two individuals and may well be immunologically atypical compared to outbred mice or outbred humans. It would be good to test this protection in an outbred mouse model, if the same level of protection is seen that be very encouraging for a human vaccine. However this is not essential for acceptance of this manuscript.

10.7554/eLife.06054.016

Author response

Reviewer \#1:

1\) A live attenuated VZV vaccine (Varivax/Zostervax) is currently used in the US. Although this vaccine is highly efficacious the immune response is short-lived and re-immunization is required. The authors show protection after a relatively short time interval (3 weeks post boost). Do the authors foresee the same problem with their HSV-2 vaccine? How long lasting is the immune response?

Studies are in progress to test the durability of the immune response in mice. We recognize that as we advance into clinical trials, additional booster doses may be needed. It should be noted however, that the HSV vaccine candidate proposed in these studies was engineered with a specific defined deletion of the gene encoding the glycoprotein D. In contrast, the Varivx/Zostervax vaccine was attenuated through serial passages in human and guinea pig cells and was sequenced after introduction into the clinic. The specific determinants of attenuation are still uncertain. The open reading frame with the most single nucleotide polymorphisms encodes the regulatory protein IE62, but IE62 studies have failed to define a specific polymorphism associated with attenuation. A more recent next-generation sequencing study of an unrelated highly attenuated VZV strain identified a stop codon mutation in ORF0 (herpes simplex virus UL56 homolog) identical to one found in vOka, suggesting that this may be one of the determinants of the attenuation genotype of live VZV vaccines (J Virol, 2012, 86(19): 10695-703). This will be addressed in future studies.

*2) The vaccine construct carries a HSV-1 gD protein. Approximately 54% of the US population has pre-existing immunity against HSV-1 (Bradley et al., JID, 2013). This could strongly impact on vaccine efficacy in humans. Would a complementing gD from a non-human herpesvirus be a better choice? The authors should discuss this*.

Future studies will address whether HSV-1 seropositivity limits the immunogenicity of the vaccine strain or whether the vaccine would be optimal in younger children who are seronegative for both HSV-1 and HSV-2. To experimentally explore this, mice infected via the skin scarification model with HSV-1 and confirmed to be seropositive will be vaccinated and challenged intravaginally with HSV-2 or vice versa. This concern will also be addressed early in the clinical development by testing the safety and immunogenicity of the vaccine in HSV-2 seronegative subjects who are either HSV-1 seropositive or seronegative. If preexisting immunity to HSV-1 interferes with the vaccine immunogenicity, we will explore complementing the vaccine strain with a gD homologue from a non-human herpesvirus as suggested by the reviewer. Other non-human herpesviruses share partial homology with HSV gD. For example, pseudorabies virus (PrV), which also binds to nectin-1 as an entry receptor, shares 30% amino acid identity and did not substitute for HSV gD in a fusion assay. However, chimeric gD molecules composed of HSV and PRV sequences did substitute, provided the first 285 amino acids were from HSV-1 (PNAS, 2004, 101(50): 17498--17503). If needed, we will explore these alternative strategies. We have added a comment in the Discussion section indicating the need to explore the impact of preexisting HSV-1 seropositivity on the immunogenicity of this vaccine strain.

*3) The authors show crossprotection/crossneutralization against HSV-1. Is this crossprotection (*[*Figure 4B*](#fig4){ref-type="fig"} *and* [*Figure 6C*](#fig6){ref-type="fig"}*) induced by the HSV-1 gD on the virus surface or not? No quantitative data is provided in* [*Figure 4*](#fig4){ref-type="fig"} *for the HSV-1 challenge. The authors should add disease scores and virus titers*.

It is unlikely that the cross-protection against HSV-1 in the intravaginal and skin scarification models is mediated by antibodies to gD-1 as the immunoblots indicate only low levels of anti-gD antibodies ([Figure 6F](#fig6){ref-type="fig"}). We speculate that antibodies targeting other viral antigens such as glycoprotein B contribute to the cross protection. This notion is supported by the observation that a humanized antibody to gB provided cross protection against HSV-1 and HSV-2 (PNAS, 2013, 110(17), 6760--5). Identification of the antigenic targets and subsequent depletion of antigen specific antibodies from the immune serum will enable us to identify the correlates of protection against both HSV-1 (cross-protection) and HSV-2. These studies will be conducted in the future. In addition, we plan to extend studies and test vaccine efficacy against clinical isolates of both HSV-1 and HSV-2. As suggested by the Reviewer, we have added the HSV-1 disease scores and skin viral loads to the manuscript ([Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}).

4\) The authors measure IgG in vaginal washes and use a neonatal FcR KO model to show that mucosal antibody is important. However, mucosal IgA is not discussed. Was that measured? Which role does it play?

We previously measured HSV specific IgA in vaginal washes but found low abundance in our ELISA assay. Although the predominant immunoglobulin by weight in the vaginal mucus of immune mice has been shown to be secretory IgA, prior studies (consistent with our work) indicate that virus specific antibody is almost entirely IgG (Parr, J Reproductive Immunology, 1998, 38; 15-3; and Parr, M., 1998, Journal of Virology, 72(6), 5137--45). Thus, we focused on IgG. It should also be noted that in humans, the primary vaginal antibody is IgG, not IgA. We have added a sentence and these references to the revised Discussion.

*5) In* [*Figure 5*](#fig5){ref-type="fig"} *the authors show that passive transfer of sera from vaccinated mice protects naive mice from challenge. The authors include a group of mice that receive \'Ig\' depleted serum. Animals in this group survive three days longer than mice in the other control groups and this result is likely statistically significant. Is this a technical issue with Ig depletion?*

We thank the reviewer for noting this as it reflected an error in the uploading of the figure between different programs. There is no significant difference between the 'Ig' depleted group and the control groups and the figure has been corrected.

*6) The authors show that the deletion of the immunodominant gD from their virus re-directs the immune response towards the less immunogenic gB, a concept that has also been proposed for HA stalk-based influenza virus vaccines. Despite high titers of antibodies against gB, the neutralization titers are very low, which is in contrast to findings with gB subunit vaccines which usually induce robust neutralization titers. The authors should discuss this*.

We hypothesize that deletion of the immunodominant gD from the virus not only redirects the immune response towards other antigens including gB but also modulates the type of antibody response from Abs that elicit neutralization to those capable of eliciting ADCC and other FcR mediated functions. This may reflect the isotype and other characteristics and may be linked to the absence of the immunomodulating effects of the gD-HVEM interaction. We have expanded the Discussion to address this.

Reviewer \#2:

*In this manuscript, the authors explore the efficacy of using a novel mechanism to attenuate Herpes simplex virus (HSV) 2 for use as a vaccine. HSV infections are an enormous global health problem and at present there is no HSV vaccine. Consequently new approaches to vaccine design are badly needed. The authors attenuate HSV-2 by deleting glycoprotein D (gD-2) and complementing the loss by a single round of replication of the virus on cells expressing HSV-1 gD (*ΔgD^-/+gD-1^*). The* ΔgD^-/+gD-1^ *virus when used as a vaccine should only replicate once in the host. To my mind the results presented here are remarkable. Subcutaneous immunization with* ΔgD^-/+gD-1^ *completely protected against intravaginal or skin challenge and prevented the establishment of latency. These data are convincing. Concerning the immune mechanisms underlying protection the authors provide evidence that protection can be transferred by Ig from immunized mice and requires that the recipient mouse express FcgammaR (presumably to mediate antibody-dependent cellular cytotoxicity as the Ig is poorly neutralizing but has ADCC activity) and FcRn (presumably to mediate transfer of Ig into the vaginal lumen)*.

*The puzzling result in terms of immune mechanism is the dramatic effect of the presence of gD-1 on the Ab response. When gD is expressed the Ab response is almost entirely gD-specific and the Abs are neutralizing. In the absence of gD antibodies specific for many HSV proteins are made. This may simply be due to an extreme immunodominance of gD. It would seem that achieving such dominance would require that gD-specific B cells have a strong advantage over B cells recognizing other HSV antigens in germinal center reactions. Perhaps immune cells, for example, T follicular helper cells that have receptors for gD, synergize with gD-specific B cells. One way to approach the question would be to determine if gD expressing HSV induces only gD-specific response in mice deficient for the known gD receptors, i.e. CD155, CD112. Such experiments, while of interest, are certainly not required to support the conclusions drawn here*.

We agree with the reviewer and plan to look at gD-specific antibodies and B cells in nectin and HVEM deficient mice. We have added this to the Discussion.

Reviewer \#3:

*This manuscript describes a novel approach to HSV2 vaccination in mice. They find that deletion of the immunodominat gD protein in the virus elicits non-neutralizing antibodies which protect against challenge very impressively. They use a variety of readouts, all giving the same answer*.

*They show that the protection is mediated by antibody, because passive transfer protects though not if Ig depleted. They show that the protection is Fc dependent and go on to show that it is likely to act through ADCC. Whether this is the direct mechanism responsible is less clear but there is at least a good correlation between this assay in vitro and protection*.

*There are important general messages here. Neutralizing antibody is not essential for protection. That is known, though often ignored, in other virus infections; here it is very well illustrated and shown that such antibodies can be harnessed by vaccination to give protection. Secondly the immunodominant antigen may not elicit protective antibody but subdominant immunogens might; genetically manipulated vaccines offer a way to address that, though what determines immunodominance often remains a mystery*.

*Can the findings be generalized to other infections? They make a reference to the RV144 HV vaccine trial where some protection was given by non-neutralizing antibodies. It would be good to cite other more convincing examples, if they exist*.

We do not yet know if these findings can be generalized to other infections. There are few examples in the literature that demonstrate the role of non-neutralizing antibodies and most of the studies are in NHP models of SIV/SHIV and one study in influenza. We have added a few of these additional references as suggested.

*A small point that is relevant to human vaccinology. BALB/c and C57B6 mice are often used to test immunogens and for challenges. However in human terms these are just two individuals and may well be immunologically atypical compared to outbred mice or outbred humans. It would be good to test this protection in an outbred mouse model, if the same level of protection is seen that be very encouraging for a human vaccine. However this is not essential for acceptance of this manuscript*.

We agree with the reviewer and are planning future experiments looking at efficacy with outbred strains of mice (such as Swiss Webster).

[^1]: These authors contributed equally to this work.
